Generate Biomedicines, Inc. GENB PHARMA
Company Overview
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.
Why Investors Should Care
Generates a return on equity of 33.0%, reflecting efficient use of shareholder capital.
Revenue has grown at a 55.9% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.14.
Recent Developments
- Dec 2025 Revenue of $31.89M (+55.9% YoY); net profit $-203.15M.
- Trailing 12 Months Year-on-year growth — revenue -37.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 55.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 55.89% |
| 1 Year: | -37.70% |
Stock Price Performance
| 1 Year: | +25.69% |
| 6 Months: | +30.65% |
| 3 Months: | +24.41% |
| 1 Month: | +10.80% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)50.89 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 33.0%.
- Compounding revenue at 55.9% over 5 years.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GENB Generate Biomedicines, Inc. PHARMA | 15.90 | -7.61 | $2.04B | 0.00% | -94.79% | 32.98% | 55.89% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 8.82M | 10.13M | 7.22M | 6.31M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 56.97M | - | 71.34M | - |
| Operating Income | -48.15M | -60.15M | -64.11M | -71.61M |
| EBITDA | -40.48M | - | -58.23M | - |
| Interest Expense | 368.00K | - | 182.00K | - |
| Pretax Income | -44.26M | - | -61.69M | - |
| Tax Provision | 56.00K | - | 28.00K | - |
| Net Income | -41.69M | -52.43M | -61.45M | -67.25M |
| Diluted EPS | -0.52 | -1.94 | -1.07 | -0.52 |
| R&D Expense | 46.83M | 59.73M | 57.81M | 64.33M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 20.46M | 31.89M |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 217.40M | 266.96M |
| Operating Income | -196.94M | -235.06M |
| EBITDA | -163.71M | -208.49M |
| Interest Expense | 2.12M | 1.14M |
| Pretax Income | -181.17M | -222.80M |
| Tax Provision | 212.00K | 163.00K |
| Net Income | -173.77M | -203.15M |
| Diluted EPS | -2.09 | -2.18 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 518.26M | 330.18M |
| Current Assets | 407.49M | 234.37M |
| Cash & Equivalents | 176.27M | 121.65M |
| Inventory | - | - |
| Receivables | 308.00K | 0 |
| Total Liabilities | 953.35M | 953.38M |
| Current Liabilities | 86.63M | 82.20M |
| Long Term Debt | - | - |
| Total Debt | 76.97M | 68.53M |
| Total Equity | -434.52M | -615.97M |
| Shares Outstanding | 127.45M | 127.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -117.75M | -200.62M |
| Investing Cash Flow | -57.73M | 116.77M |
| Financing Cash Flow | 91.33M | 28.06M |
| Capital Expenditure | -3.45M | -3.51M |
| Free Cash Flow | -121.20M | -204.13M |
| Net Change in Cash | -84.15M | -55.79M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | -962.6% | -737.0% |
| Net Margin % | -849.4% | -637.0% |
| ROE % | 40.0% | 33.0% |
| ROCE % | -45.6% | -94.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Flagship Pioneering LLC | 48.83% | 62.67M | $1.07B |
| 2 | FMR, LLC | 4.07% | 5.22M | $89.50M |
| 3 | Capital World Investors | 3.28% | 4.22M | $72.26M |
| 4 | Braidwell LP | 2.56% | 3.28M | $56.29M |
| 5 | Price (T.Rowe) Associates Inc | 1.68% | 2.16M | $36.96M |
| 6 | NORGES BANK | 1.63% | 2.09M | $35.90M |
| 7 | Arch Venture Management, Llc | 1.51% | 1.94M | $33.33M |
| 8 | Harbourvest Partners, LLC | 1.34% | 1.72M | $29.52M |
| 9 | Blackrock Inc. | 1.29% | 1.66M | $28.45M |
| 10 | Baker Bros. Advisors, LP | 1.11% | 1.42M | $24.40M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GENB
Top Generate Biomedicines (GENB) Competitors 2026 - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxQMHpDLXBNa2VYbUZId1luWnVudFgzUXFXUFpwV2doLVYzVVJzWEEtcDRqOUtmSW9jM0NSQi1JM1FaQnRaSURrX3pkTjRfNXdSVVZUamkzS0U4VnlwQkt3c1pkOTRwRFdWWm9DQzBmUlRPcGFEd3hmcUF5QkNHcGFVeA?oc=5" target="_…
Five September talks will stream online from Generate Biomedicines - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNb2FfOUY0RVlSMEozVDQyYzhXNzdZTzBTaVFJXzRTdE1SdjZvSkQ0dlNwbkN2X1ZRNlpacGExWndHelRjeDlLN0UzZ0VFOUFIa19UVkh6NV91dkVteEplWUJJUDZKWmhrNS1SYjVSQjNjQ3JwYUU4OENSNTY5SFdpOXB3elg4dGxOZ0owdF…
GENB Stock Price and Chart — NASDAQ:GENB - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTFBVT3RudDJ3bnh2NVlYYkJYcGhxOUJGeG5TOTZBV1pKWmxzdzI2MDd0QWRPVnhhYmd3Z0hfWjhDMGIyVENJdkVfSDgxQ09Tb0hHb2VDSWRQdTE2Vnh5?oc=5" target="_blank">GENB Stock Price and Chart — NASDAQ:GENB</a…
Generate Biomedicines (GENB) Stock Looks Pricey On Book Value Yet Strong On Returns - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNUFRaZ3J0NFNsdzZDMG9aYVFLQ05zYjVLRXhob3hFUzBPVkgyU3laMFFZMTZ5bVpuUGZPbHhrVFo3MHo0dHR4dkZhVk9FcFBwc1Jva0drUkNHYzR3UW55dFhGU3dORThWNFR0anpBLWNIRVREOUhRV2JKLWh5SUxaSXZlRVRyWTlYRzVVNT…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE51UmJlZ1EwS01oeUxCUkNFbHQyOHJEalZjLU9zbDJDWklRLV9ja2d0c3ZqZVpsdzZ2LXZDSDRTVVRISjhGdFFwb20wd0xwTUlW?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMiTEFVX3lxTFBHMGhHdmJlZ2JuemZSbU1wNDBqQ29KWjYwWjg2MW5faWtvT1Rla2MxV1otRF9helF6bTBvaGFuZl9NeGw3dmVmNGIzSVE?oc=5" target="_blank">Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Ch…
GENB — Frequently Asked Questions
What is the current share price of Generate Biomedicines, Inc. (GENB)?
As of 2026-09-19 21:16 PDT, Generate Biomedicines, Inc. (GENB) trades at $15.90 on NasdaqGS. Its 52-week range is $11.21 to $20.38.
What is the market capitalisation of GENB?
Generate Biomedicines, Inc. (GENB) has a market capitalisation of $2.04B on NasdaqGS.
What is the P/E ratio of GENB?
GENB trades at a trailing price-to-earnings (P/E) ratio of -7.61. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.82.
What is the return on equity (ROE) of GENB?
GENB has a return on equity (ROE) of 32.98%. Its return on capital employed (ROCE) is -94.79%.
Is GENB a good stock to buy?
This page provides a data-driven analysis of Generate Biomedicines, Inc. (GENB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.